CoChat

Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme

Lawn, Stephen D, Bekker, Linda-Gail, Myer, Landon, Orrell, Catherine, Wood, Robin · 2005 · AIDS
Cited by 129

The DOI matches its Crossref record.

Abstract

We read with interest the recent paper by Lortholary et al. [1] describing cryptococcocal immune reconstitution disease (IRD) in France. This is an increasingly recognized complication of the initial weeks of antiretroviral treatment (ART) [1–5]. However, to our knowledge, the frequency of cryptococcocal IRD in low-income countries has not previously been reported. We run a community-based ART programme in Gugulethu, Cape Town, South Africa [6]. Between September 2002 and November 2004, 434 treatment-naive patients started triple-drug ART according to WHO 2002 treatment guidelines [7]. The patients’ mean age was 34 years, their median blood CD4 cell count was 86 cells/μl [interquartile range (IQR) 46–146 cells/μl], and the median plasma HIV load was 76 337 copies/ml (IQR 32 723–192 772 copies/ml). A total of 137 patients (32%) had WHO stage 4 disease, and among these cryptococcal meningitis was the AIDS-defining illness in 18 (13%). These diagnoses were made a median of 7 months (range 2–24 months) before the initiation of ART. According to national guidelines, cryptococcal meningitis was treated with fluconazole 400 mg/day for 8 weeks followed by 200 mg/day as secondary prophylaxis. At data censorship in February 2005, the median follow-up was 46 weeks. During a total of 460 person-years of observation (PYO), nine patients developed either recurrent (n = 6) or new (n = 3) symptomatic cryptococcal disease of the central nervous system (Table 1). The median duration of ART at the onset of symptoms was 4 weeks. In the first, second and third months of ART, disease incidence based upon the time of symptom onset was 18.2 cases/100 PYO [95% confidence interval (CI) 8.2–40.6], 6.2 cases/100 PYO (95% CI 1.6–25.1) and 0 cases/100 PYO, respectively. Only one case of cryptococcal disease occurred after 12 weeks’ ART. Six of the nine patients (66%) died and cryptococcal disease accounted for six out of 22 total deaths (27%) during the first 3 months of ART.Table 1: Features of nine cases of central nervous system cryptococcosis during the initial weeks of antiretroviral treatment.IRD results from the rapid restoration of immune function, leading to an exacerbation of partly treated opportunistic infections or unmasking of previously undiagnosed subclinical infections [8]. Several factors have suggested that IRD was the likely mechanism underlying the presentation of most or all of these cases of cryptococcosis: the very high incidence density rate within the initial weeks of ART, the sudden onset, the typically rapid evolution and fulminant clinical course. Of those with a previous history of cryptococcosis, one-third developed probable IRD. Although this proportion is comparable with other series [2,5], the mortality rate in our series is higher and represents a substantial problem that needs to be addressed to reduce the early mortality during ART among patients in resource-limited settings. Live organisms, dead organisms or their shed antigens may trigger IRD [8]. Among cases from whom viable organisms are cultured, symptoms may either be caused by IRD or simply represent new opportunistic disease. IRD case definitions that exclude clinically suspected cases with positive cultures increase the specificity of IRD diagnoses but may limit sensitivity. Of the nine patients described, seven had sterile cultures; although cultures from the remaining two cases were positive, a review of their clinical presentation suggested that IRD was potentially the underlying mechanism. Cryptococcocal IRD is likely to be increasingly frequently encountered in ART programmes in sub-Saharan Africa for several reasons. First, ART programmes in the region are currently inundated with large numbers of patients with very advanced immunodeficiency; such patients are at the greatest risk of developing IRD. Second, HIV-associated cryptococcal disease is common in the region. Third, the local standard of care for cryptococcal meningitis is treatment with oral fluconazole, which is supplied free of charge by the manufacturer. Fluconazole is a fungistatic drug, which is broadly effective as secondary prophylaxis, but has far less efficacy than amphotericin in clearing the organism during the initial treatment phase [9]. We suggest that the use of this agent for primary treatment may increase the risk of cryptococcal antigen persistence within the cerebrospinal fluid (CSF), possibly increasing the risk of IRD during ART. Among those with a previous history of cryptococcosis, an analysis of CSF before the initiation of ART might be used to identify those with a persistent antigen burden who might then be retreated to reduce the fungal burden before starting ART. However, this strategy may be impractical in view of the huge logistic challenges facing many ART programmes in low-income countries. However, the optimum interval between the treatment of cryptococcal meningitis and the initiation of ART needs to be defined, and clinicians should be made a

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.aids.0000191232.16111.f9

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 129

Metadata

Authors
Lawn, S. D., Bekker, L.-G., Myer, L., Orrell, C., & Wood, R.
Venue
AIDS
Published
2005-11-18
Volume
19
Issue
17
Pages
2050-2052
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2087634902
Cited by
129
References
0
FWCI
7.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. https://app.cochat.ai/papers/10.1097/01.aids.0000191232.16111.f9
The paper
Lawn, S. D., Bekker, L.-G., Myer, L., Orrell, C., & Wood, R. (2005). Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. https://doi.org/10.1097/01.aids.0000191232.16111.f9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.